CSE: IN
OTCQB: IMLFF

Suite 350– 409 Granville ST
Vancouver, BC, Canada V6C-1T2
Tel: 604.669.7207
Email: info@inmedpharma.com
www.inmedpharma.com

InMed to Present at Cannabis-Based Therapies Conference

Vancouver, BC – November 23, 2016 - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), announced today that it will present at the 'Cannabis-Based Therapies' medical conference on Wednesday, November 30th and Thursday, December 1st, 2016 at the Hyatt Centric Fisherman's Warf in San Francisco, CA.

Dr. Sazzad Hossain, InMed's Chief Scientific Officer, will participate as a panel member during the session entitled "Regulatory Hurdles Impacting Cannabis-Based Research" as well as presenting a case study entitled "Leveraging the Pharmacobiology of Cannabinoid Receptors for Drug Discovery and Pharmaceutical Drug Development". This presentation will highlight the validation of InMed's proprietary bioinformatics analysis tool being utilized for drug-disease targeting and expedited pre-clinical testing of new cannabinoid-based drugs.

More information on this conference, organized by CBI - a division of UBM, is available at: www.cbinet.com/cannabistherapies.com

About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com

Contact: InMed Pharmaceuticals Inc.

Chris Bogart
SVP, Investor Relations and Corporate Strategy
T: 604.669.7207
E: chris@inmedpharma.com